https://www.live-feeds.com/feed/founded-by-metsera-backers-sentivera-emerges-with-1-5b-inflammatory-disease-dealContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/founded-by-metsera-backers-sentivera-emerges-with-1-5b-inflammatory-disease-dealhttps://www.live-feeds.com/feed/founded-by-metsera-backers-sentivera-emerges-with-1-5b-inflammatory-disease-deal#u50109Thu, 27 Aug 2026 13:01:27 +0000Sentivera, a biotech backed by Metsera investors, has been founded with a $1.5 billion deal to develop an inflammatory disease treatment. The company has obtained an exclusive license agreement from China's Haisco for a pre-clinical drug. This deal is Haisco's second major partnership this year, worth up to $1.5 billion-plus. Sentivera aims to advance the development of this immunology asset.Why it mattersThe deal highlights the growing interest in immunology and inflammatory disease treatments. Haisco, a Chinese company, is partnering with US venture capital firms, including ARCH Ve